Latest Articles

Publication Date
Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …

Published: Nov. 22, 2025, midnight
How We Can Optimize Dysmenorrhea Treatment: Real-World Results from a Cross-Sectional, Multi-Center Study.

Dysmenorrhea is a common and disabling condition in women. We investigate the prevalence of endocrine dysmenorrhea treatment (EDT) and the use of pain medication in dysmenorrhea patients without surgically treated …

Published: Nov. 17, 2025, midnight
The Evolution of In Vitro Fertilization Practices in Saudi Arabia: Historical Perspectives and Future Directions.

In vitro fertilization (IVF) has revolutionized assisted reproductive technologies (ART), profoundly transforming infertility treatment since its inception. This procedure involves fertilizing an egg with sperm in a controlled laboratory environment, …

Published: Nov. 16, 2025, midnight
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …

Published: Nov. 7, 2025, midnight
Psychosocial Factors and Disease Localization as Independent Predictors of Sexual Dysfunction in Women with Endometriosis.

Background: This study examines the impact of endometriosis on sexual function, focusing on disease localization, pain severity, and psychosocial factors. It integrates the rASRM and Enzian classification systems to explore …

Published: Nov. 2, 2025, midnight
Potency of oral gonadotropin-releasing hormone antagonist as endometriosis-associated pain novel treatments: An updated meta-analysis of randomized controlled trials.

Elagolix, Linzagolix, and Relugolix, as oral gonadotropin-releasing hormone antagonists, have emerged as promising treatments for endometriosis-associated pain.

Published: Nov. 1, 2025, midnight
Diagnostic Delays and Economic Burden in Japanese Women with Endometriosis: A Cross-Sectional Analysis.

This study investigates the association between diagnostic delay (DD) and clinical and behavioral variables among Japanese women with endometriosis, and explores an optimal cut-off point distinguishing short and long DD.

Published: Oct. 25, 2025, midnight
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - The Manila Times

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times

Published: Oct. 24, 2025, 3:57 p.m.
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region.

Catamenial pneumothorax is a rare clinical condition first described over seven decades ago. It typically occurs within 72 hours before or after menstruation and is most frequently observed in women …

Published: Oct. 18, 2025, midnight
Understanding Peritoneal Fluid Estrogen and Progesterone Concentrations Permits Individualization of Medical Treatment of Endometriosis-Associated Pain with Lower Doses, Especially in Adolescents Not Requiring Contraception.

Objectives: The aim of this study was to review the importance of peritoneal fluid steroid hormone concentrations to understand the mechanism of hormonal medical treatment of endometriosis-associated pain. Design: The …

Published: Oct. 12, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!